Gadeta to Present Data on Tumor-Specific Cell Therapies at Leading Scientific Conferences
- GDT002 shown to have a potent anti-tumor activity across a broad spectrum of solid and liquid tumors
- Ovarian cancer selected from broad screening of solid tumor types as the indication for GDT002
Utrecht, Netherlands and Boston, Mass., 28 March 2022: Gadeta B.V. (‘Gadeta’), a clinical-stage company developing innovative, gamma delta (γδ) T-cell receptor (TCR)-based immunotherapies for every cancer patient, is pleased to announce that Chief Executive Officer Marcel Zwaal and Chief Scientific Officer Mark Throsby will be presenting data on γδ TCR-based immunotherapies for solid tumors at the following upcoming scientific conferences:
